Sign In
Buy CODX
$2.61
-0.0300 (-1.14%)
At Close: Jul 10, 2026
Co-Diagnostics Invited to Participate in NPOC Tuberculosis Diagnostics Workshop in Bangkok, Thailand
09:00am, Wednesday, 08'th Jul 2026
Invited by the Stop TB Partnership and the Global Fund to participate as a manufacturer partner Workshop brings together national TB programs, researchers, donors, and technical agencies from 21 coun
Co-Diagnostics Completes Clinical and Analytical Studies in Preparation for FDA 510(k) Submission of Upper Respiratory Point-of-Care Test
09:00am, Wednesday, 01'st Jul 2026
More than 1,400 patients enrolled across 9 clinical sites; analytical performance testing included 27 individual studies and over 10,000 PCR test cup runs Analytical data to support concurrent 510(k)
Co-Diagnostics Vector Smart® Division Expands Footprint to 21 States
09:00am, Thursday, 25'th Jun 2026
Expansion coincides with Co-Dx webinar for prospective mosquito abatement district customers in honor of National Mosquito Control Awareness Week SALT LAKE CITY, June 25, 2026 /PRNewswire/ -- Co-Diag
Co-Diagnostics Advances Latin American Commercialization Strategy for Co-Dx™ PCR Pro® with Mexico Distributor Agreement
09:00am, Thursday, 11'th Jun 2026
Longstanding distribution partner to support future deployment of Co-Dx™ PCR Pro ® and expanding menu of molecular diagnostics products across a key Latin American market SALT LAKE CITY, June 11, 2
Co-Diagnostics and CoSara Advance Ebola PCR Test Development and Co-Dx™ PCR Point-of-Care Platform Capabilities
09:00am, Tuesday, 02'nd Jun 2026
Dual-assay strategy designed to support outbreak response and surveillance efforts in affected regions Potential blood-based Ebola assay would represent an important expansion of Co-Dx™ PCR point-of
Is Co-Diagnostics National Security's Next Diagnostic Pick?
11:03am, Thursday, 28'th May 2026
A structural shift is underway in the biodefense landscape. The declaration of a Public Health Emergency of International Concern (PHEIC) by the World Health Organization on May 17, 2026, for the Bund
Co-Diagnostics Advances Ebola PCR Assay Development Strategy with Joint Venture CoSara
09:00am, Tuesday, 26'th May 2026
Joint development strategy has been developed to address international deployment requirements if current outbreak continues or expands globally SALT LAKE CITY, May 26, 2026 /PRNewswire/ -- Co-Diagnos
Co-Diagnostics Announces $3.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
10:54pm, Tuesday, 19'th May 2026
SALT LAKE CITY, May 19, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx", or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of m
Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
09:00am, Tuesday, 19'th May 2026
Recent pathogens illustrate need for improved situational awareness capabilities, such as those provided by the Co-Dx PCR point-of-care platform Follows outbreak of Ebola and WHO emergency declaration
Co-Diagnostics, Inc. (CODX) Q1 2026 Earnings Call Transcript
07:10pm, Thursday, 14'th May 2026
Co-Diagnostics, Inc. (CODX) Q1 2026 Earnings Call Transcript
Co-Diagnostics Reports First Quarter 2026 Financial Results
04:01pm, Thursday, 14'th May 2026
Advancing Global Commercialization Through CoSara Regulatory Progress and Regional Expansion Executing Clinical Strategy with Upper Respiratory Submission Preparation and TB Study Initiation Expanding
Lease execution highlights transition from approval to development and advances localized manufacturing strategy in the Kingdom of Saudi Arabia in accordance with Vision 2030 SALT LAKE CITY, May 8, 20
Co-Diagnostics Announces First Quarter 2026 Earnings Release Date and Webcast
09:00am, Thursday, 30'th Apr 2026
SALT LAKE CITY, April 30, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of
Co-Diagnostics Invited to Present at Stop TB Partnership Summit in Washington, D.C.
09:00am, Thursday, 16'th Apr 2026
MTB test on Co-Dx PCR platform* to be presented at roundtable with Stop TB Partnership, U.S. Department of State, and global stakeholders SALT LAKE CITY, April 16, 2026 /PRNewswire/ -- Co-Diagnostics,
Co-Diagnostics to Showcase Co-Dx PCR Platform and CE-IVD Solutions at ESCMID 2026 in Munich, Germany
09:00am, Tuesday, 14'th Apr 2026
Company to engage with global customers and distributors while expanding international commercial relationships SALT LAKE CITY, April 14, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (t
